Case studies for practical food effect assessments across BCS/BDDCS class compounds using in silico, in vitro, and preclinical in vivo data

AAPS Journal

Volumn 15, Issue 1, 2013, Pages 143-158

  Heimbach, Tycho ^a   Xia, Binfeng ^a   Lin, Tsu Han ^a   He, Handan ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

absorption modeling; BCS BDDCS; food effect prediction; human PBPK model; oral bioavailability

Indexed keywords

NEW DRUG; NVS 001; NVS 113; NVS 169; NVS 406; NVS 562; NVS 701; NVS 732; UNCLASSIFIED DRUG;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; COMPUTER MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; FOOD; FOOD DRUG INTERACTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHYSICAL CHEMISTRY; PREDICTION; SIMULATION; SINGLE DRUG DOSE;

ANIMALS; BIOPHARMACEUTICS; COMPUTER SIMULATION; DOGS; DRUG DISCOVERY; FOOD-DRUG INTERACTIONS; HUMANS; MICE; RATS;

EID: 84871957696     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9419-5     Document Type: Article

References (48)

1. Fleisher D, Li C, Zhou Y, Pao LH, Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet. 1999;36(3):233-54. (Pubitemid 29178760)
2. US FDA. Food-effect bioavailability and fed bioequivalence studies. In: Guidance for industry. http://www.fda.gov/downloads/regulatoryinformation/ guidances/ucm126833.pdf. 2002. Accessed 02 Jun 2012.
3. Zhang X, Lionberger RA, Davit BM, Yu LX. Utility of physiologically based absorption modeling in implementing quality by design in drug development. AAPS J. 2011;13(1):59-71. doi: 10.1208/s12248-010-9250-9.
4. Hendeles L, Weinberger M, Milavetz G, Hill 3rd M, Vaughan L. Food-induced "dose-dumping" from a once-a-day theophylline product as a cause of theophylline toxicity. Chest. 1985;87(6):758-65. (Pubitemid 15063777)
5. Wilder BJ, Leppik I, Hietpas TJ, Cloyd JC, Randinitis EJ, Cook J. Effect of food on absorption of dilantin kapseals and mylan extended phenytoin sodium capsules. Neurology. 2001;57(4):582-9. (Pubitemid 32782983)
6. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification - the correlation of in-vitro drug product dissolution and in-vivo bioavailability. Pharmaceut Res. 1995;12(3):413-20.
7. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22(1):11-23. doi: 10.1007/s11095-004-9004-4. (Pubitemid 40558141)
8. Benet L. Z. WCY. Using a biopharmaceutics drug disposition classification system to predict bioavailability and elimination characteristics of new molecular entities. Somerset, NJ: NJDMDG. 2006.
9. Custodio JM, Wu C-Y, Benet Leslie Z. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev. 2008;60(6):717-33.
10. Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to over 900 drugs. AAPS J. 2011;13(4):519-47. doi: 10.1208/s12248-011-9290-9.
11. Singh A, Worku ZA, Van den Mooter G. Oral formulation strategies to improve solubility of poorly water-soluble drugs. Expert Opin Drug Deliv. 2011;8(10):1361-78. doi: 10.1517/17425247.2011.606808.
12. Lui CY, Amidon GL, Berardi RR, Fleisher D, Youngberg C, Dressman JB. Comparison of gastrointestinal Ph in dogs and humans - implications on the use of the beagle dog as a model for oral absorption in humans. J Pharm Sci. 1986;75(3):271-4. (Pubitemid 16136927)
13. Meyer JH, Dressman J, Fink A, Amidon G. Effect of size and density on canine gastric-emptying of nondigestible solids. Gastroenterology. 1985;89(4):805-13. (Pubitemid 15015296)
14. Akimoto M, Nagahata N, Furuya A, Fukushima K, Higuchi S, Suwa T. Gastric pH profiles of beagle dogs and their use as an alternative to human testing. Eur J Pharm Biopharm. 2000;49(2):99-102. (Pubitemid 30126056)
15. Lentz KA, Quitko M, Morgan DG, Grace JE. Development and validation of a preclinical food effect model. J Pharm Sci. 2007;96(2):459-72. doi: 10.1002/Jps.20767. (Pubitemid 46363575)
16. Russell WMS, Burch RL. The principles of humane experimental technique. London: Methuen & Co. Special edition published by Universities Federation for Animal Welfare (UFAW), 1992; 1959.
17. Huang SM. PBPK as a tool in regulatory review. Biopharm Drug Dispos. 2012;33(2):51-2. doi: 10.1002/Bdd.1777.
18. Lukacova V, Woltosz WS, Bolger MB. Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data. AAPS J. 2009;11(2):323-34. doi: 10.1208/s12248-009-9107-2.
19. Parrott N, Lukacova V, Fraczkiewicz G, Bolger MB. Predicting pharmacokinetics of drugs using physiologically based modeling - application to food effects. AAPS J. 2009;11(1):45-53. doi: 10.1208/s12248-008-9079-7.
20. Vieira MLT, Zhao P, Berglund EG, Reynolds KS, Zhang L, Lesko LJ, et al. Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor. Clin Pharmacol Ther. 2012;91(4):700-8. doi: 10.1038/clpt.2011.305.
21. Shaffer CL, Scialis RJ, Rong HJ, Obach RS. Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism-based adverse events. Biopharm Drug Dispos. 2012;33(2):72-84. doi: 10.1002/Bdd.1768.
22. Shono Y, Jantratid E, Dressman JB. Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir. Eur J Pharm Biopharm. 2011;79(2):349-56. doi: 10.1016/j.ejpb.2011.04.005.
23. Shono Y, Jantratid E, Janssen N, Kesisoglou F, Mao Y, Vertzoni M, et al. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. Eur J Pharm Biopharm. 2009;73(1):107-14. doi: 10.1016/j.ejpb.2009.05.009.
24. Shono Y, Jantratid E, Kesisoglou F, Reppas C, Dressman JB. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. Eur J Pharm Biopharm. 2010;76(1):95-104. doi: 10.1016/j.ejpb.2010.05.009.
25. Nicolaides E, Symillides M, Dressman JB, Reppas C. Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharm Res. 2001;18(3):380-8. (Pubitemid 32595828)
26. Dressman JB, Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci. 2000;11:S73-80.
27. Parrott N, Lave T. Prediction of intestinal absorption: comparative assessment of GASTROPLUS (TM) and IDEA (TM). Eur J Pharm Sci. 2002;17(1-2):51-61. (Pubitemid 35287171)
28. Kuentz M, Nick S, Parrott N, Rothlisberger D. A strategy for preclinical formulation development using GastroPlus (TM) as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. Eur J Pharm Sci. 2006;27(1):91-9. doi: 10.1016/j.ejps.2005.08.011. (Pubitemid 41728259)
29. Yu LX, Amidon GL. Characterization of small intestinal transit time distribution in humans. Int J Pharm. 1998;171(2):157-63. (Pubitemid 29023108)
30. Heimbach T, Lakshminarayana SB, Hu WY, He HD. Practical anticipation of human efficacious doses and pharmacokinetics using in vitro and preclinical in vivo Data. AAPS J. 2009;11(3):602-14. doi: 10.1208/s12248-009-9136-x.
31. Xia B, Heimbach T, Lin TH, He H, Wang Y, Tan E. Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions. Canc Chemother Pharmacol. 2012;69(6):1567-82. doi: 10.1007/s00280-012-1863-5.
32. Kesisoglou F, Wu YH. Understanding the effect of API properties on bioavailability through absorption modeling. AAPS J. 2008;10(4):516-25. doi: 10.1208/s12248-008-9061-4.
33. Jones HM, Parrott N, Ohlenbusch G, Lave T. Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling. Clin Pharmacokinet. 2006;45(12):1213-26. (Pubitemid 44904824)
34. Kostewicz ES, Wunderlich M, Brauns U, Becker R, Bock T, Dressman JB. Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine. J Pharm Pharmacol. 2004;56(1):43-51. doi: 10.1211/ 0022357022511. (Pubitemid 38195327)
35. De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, Gilissen RAHJ. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos. 2007;35(10):1766-80. doi: 10.1124/dmd.107.015644. (Pubitemid 47481568)
36. De Buck SS, Sinha VK, Fenu LA, Gilissen RA, Mackie CE, Nijsen MJ. The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab Dispos. 2007;35(4):649-59. doi: 10.1124/dmd.106.014027. (Pubitemid 46513269)
37. Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci. 2002;91(5):1358-70. doi: 10.1002/jps.10128. (Pubitemid 34651198)
38. Meier Y, Eloranta JJ, Darimont J, Ismair MG, Hiller C, Fried M, et al. Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab Dispos. 2007;35(4):590-4. doi: 10.1124/dmd.106. 013342. (Pubitemid 46513261)
39. Chen ML, Yu L. The use of drug metabolism for prediction of intestinal permeability. Mol Pharmaceut. 2009;6(1):74-81. doi: 10.1021/Mp8001864.
40. Mithani SD, Bakatselou V, TenHoor CN, Dressman JB. Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharmaceut Res. 1996;13(1):163-7. (Pubitemid 26076314)
41. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci. 2001;58(7):931-59. (Pubitemid 32652819)
42. Mithani SD, Bakatselou V, TenHoor CN, Dressman JB. Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm Res. 1996;13(1):163-7. (Pubitemid 26076314)
43. Lentz KA. Current methods for predicting human food effect. AAPS J. 2008;10(2):282-8. doi: 10.1208/s12248-008-9025-8.
44. US FDA. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. In: Guidance for industry. 2000. http://www.fda.gov/ downloads/Drugs/./Guidances/ucm070246.pdf. Accessed 02 Jun 2012.
45. Fagerholm U, Johansson M, Lennernas H. Comparison between permeability coefficients in rat and human jejunum. Pharm Res. 1996;13(9):1336-42. (Pubitemid 26344978)
46. Tse FLS. Pharmacokinetics in drug discovery and development: nonclinical studies. In: Welling PG, Tse FLS, editors. Pharmacokinetics: regulatory, industrial, academic perspectives. 2nd ed. New York: Dekker; 1995. p. 300-6.
47. Jones RD, Jones HM, Rowland M, Gibson CR, Yates JW, Chien JY, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution. J Pharm Sci. 2011. doi: 10.1002/jps.22553.
48. Ring BJ, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RD, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessement of prediction methods of human clearance. J Pharm Sci. 2011. doi: 10.1002/jps.22552.